


DiBiCol®

DIAGNOSING INFLAMMATORY BOWEL DISEASES

Clinical reasons for requesting DiBiCol - analysis

- User data compiled from over 30 IBD units in Sweden over 2 years -



Statistics from the first two years of DiBiCol use show that 65% of all tests have been performed to diagnose difficult cases, either IBD unclassified (IBDU*) or indeterminate colitis (IC**). The second largest category, 16%, comprises of new patients with IBD-like symptoms.

InDex Pharmaceuticals was founded in 2000 and is based at Karolinska Institutet, Stockholm. The company develops compounds to treat diseases within a variety of therapeutic areas, including inflammation and cancer.

InDex Pharmaceuticals also develops multigene-based diagnostics designed to improve gastrointestinal disease classification assuring that the most appropriate treatment regime is selected for a patient.

InDex
Pharmaceuticals

Scheelelaboratoriet, Karolinska Institutet
Scheeles väg 2, SE-171 77 Stockholm, Sweden

The sure and

Fast

track

to an IBD

diagnosis

DiBiCol®

DIAGNOSING INFLAMMATORY BOWEL DISEASES

DiBiCol®

*Improving patient quality of life by
choosing the right treatment options*

DiBiCol enables a quick and accurate diagnosis of inflammatory bowel diseases (IBD). DiBiCol is used to differentiate between ulcerative colitis (UC) and Crohn's disease (CD) and to exclude the less severe condition irritable bowel syndrome (IBS).

A new method to classify IBD

DiBiCol is a PCR[§]-based method that monitors seven proprietary biomarkers specific for UC or CD in a single colonic biopsy. By using seven biomarkers coupled with a specially designed algorithm, a diagnosis can be made with a high degree of certainty.

DiBiCol has been verified in three clinical studies including more than 300 patients and the results were published in *Gastroenterology*¹ June 2008. DiBiCol received market approval in Sweden late 2009.

Challenges in diagnosing IBD

Today, there are about 3 million people in the EU and the US that suffer from inflammatory bowel disease of which 10-15 percent have an unclassified inflammatory bowel disease, so called IBDU. It is not uncommon that a previously established diagnosis is changed during the disease history of a patient. Using DiBiCol allows treating physicians to prescribe the most appropriate treatment options on an individual patient basis.

[§]Polymerase Chain Reaction, a molecular biologic method that multiplies a certain DNA-sequence.

Reference:

¹ von Stein P, Lofberg R, Kuznetsov NV, Gielen AW, Persson J-O, Sundberg R, Hellstrom K, Eriksson A, Befrits R, Ost A, von Stein O. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome. *Gastroenterology*. June 2008

Reasons to use DiBiCol

To provide a diagnosis:

- In cases of IBDU*
- In cases of IC**
- In patients presenting IBD-like symptoms for the first time
- If a change in diagnosis is contemplated
- Before surgery to ensure that the right surgical procedure is adopted
- To confirm a diagnosis of CD or UC
- To ensure most appropriate medical management

* Unclassified inflammatory bowel disease

** Indeterminate colitis

Contact Information

Ordering:

InDex Pharmaceuticals AB:
Phone, +46 8 508 847 08
order@indexpharma.com

Technical assistance:

InDex Pharmaceuticals AB:
Phone, +46 8 508 847 48
support@indexpharma.com

Patients should contact their physician.
Please find more information at www.indexpharma.com